Corynebacterium striatum prosthetic valve endocarditis with severe aortic regurgitation successfully treated with transcatheter aortic valve replacement.
Syed Yaseen NaqviIbrahim G SalamaCraig NarinsThomas StuverPublished in: BMJ case reports (2018)
We describe the case of a 69-year-old man with a history of bioprosthetic aortic valve replacement who presented with Corynebacterium striatum prosthetic valve endocarditis (PVE) complicated by severe aortic insufficiency with refractory cardiogenic shock despite antibiotic therapy. He was considered a prohibitive-risk surgical candidate due to co-morbid conditions and off-label valve-in-valve transcatheter aortic valve replacement (TAVR) was performed after detailed multidisciplinary evaluation. He recovered well without recurrent infection following completion of antibiotics and transthoracic echocardiogram at 12 months showed a normal functioning prosthetic valve. To our knowledge, this is the first reported case of native or PVE treated with TAVR.
Keyphrases
- aortic valve
- transcatheter aortic valve replacement
- aortic valve replacement
- aortic stenosis
- transcatheter aortic valve implantation
- healthcare
- left ventricular
- ejection fraction
- heart failure
- bariatric surgery
- mesenchymal stem cells
- drug induced
- coronary artery disease
- cell therapy
- prefrontal cortex
- coronary artery
- replacement therapy